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Abstract
Background: This study aimed to explore differences in links between negative symptoms and neurocognitive
deficits in adolescent and adult patients with first-episode schizophrenia. Schizophrenia is a mental disorder often
characterized by positive and negative symptoms, reduced emotional expression, excitatory status, and poor
cognitive ability. The severity of negative symptoms in patients with schizophrenia was reported to be more
related to poor quality of life, weak functional ability, and heavy burden from families than with the severity
of positive symptoms. Previous studies suggested correlations between the severity of negative symptoms in
patients with schizophrenia and neurocognitive deficits.
Methods: This study included 92 patients (33 adolescents and 59 adults) with first-episode schizophrenia and
57 healthy people matched by age and education level. Neurocognitive functions and clinical symptoms were
assessed using a standardized questionnaire.
Results: Patients with first-episode schizophrenia showed neurocognitive deficits in most neuropsychological
assessments compared with healthy people. With the variable of education level controlled, the negative factor
score of adolescent patients with first-episode schizophrenia was strongly correlated with more time spent in
part 1 (r = .646) and part 2 (r = .663) of the trail making test, and moderately correlated to more perseverative
errors (r = .425) of the Wisconsin card sorting test and fewer correct trials 2 (r = −.425) of the continuous performance
test. However, no such correlations were found in adult patients.
Conclusions: This study indicated significant correlations between negative symptoms and most neurocognitive
functions in patients with first-episode schizophrenia, with a stronger correlation in adolescent patients.
Trial registration: The trial registration number is ChiCTR-COC-14005302, while retrospectively registered on
January 5, 2014.
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Background
Schizophrenia is a mental disorder often described in
terms of hallucination and abnormal social behavior,
including poor rapport and social isolation. It affects
about 0.3–0.7 % [1] of people at some point (the peak
age of onset is 18–25 years [2]) in their lives and ac-
counts for approximately 1 % of disability-adjusted life
year all over the world [3]. Patients with schizophrenia
have been reported to have abnormities in brain struc-
ture and function [1, 4]. The causes of schizophrenia
have been widely investigated, and many studies have
suggested genetics, prenatal and adolescent neurodeve-
lopment, psychological health, and social living envir-
onment as common risk factors [2, 5, 6].
Schizophrenia is often characterized by positive and
negative symptoms, reduced emotional expression, exci-
tatory status, and poor cognitive ability. The positive and
negative syndrome scale (PANSS) is a 30-item rating
scale designed by Kay to assess the severity of schizo-
phrenia symptoms. Literature research suggested that a
five-factor model, which consists of positive, negative,
disorganized–concrete, excited, and anxious–depressive
factor, better captured the PANSS structure in patients
with schizophrenia [7–14].
Generally, negative symptoms refer to poor emotional
reactions or thought processes, including emotion impover-
ishment, speech barrier, thought inflexibility, and decreased
activity. It has been reported that severity of negative symp-
toms in patients with schizophrenia was more related to
poor quality of life [15], weak functional ability [16] and
heavy burden from families, compared with the severity of
positive symptoms [17]. Moreover, patients with schizo-
phrenia having obvious negative symptoms often had a
history of poor social adaptability before the onset of
illness, and their responses to medication were often lim-
ited [18]. The present study focused on negative symp-
toms owing to their serious influence on human life.
Adolescence is a key period of neurological and psy-
chological development. If psychosis occurs in one’s late
adolescence when the frontal lobe is still developing,
some extraordinary differences may exist in both neuro-
cognitive deficits and clinical symptoms [19], compared
with an adult patient with schizophrenia. A 5-year follow-
up clinical study on very early-onset schizophrenia, using
magnetic resonance imaging (MRI), showed damage pro-
cesses in brain regions of adolescent patients with schizo-
phrenia. However, adult cognitive deficits are known to
be mediated by environmental factors [20]. A latest
study also showed that adolescent patients with schizo-
phrenia performed worse than adult patients in tasks of
working memory, language, and motor function [21].
In addition, previous studies have suggested correlations
between negative symptoms in patients with schizophrenia
and neurocognitive deficits involving intelligence, executive
function, sustained-attention function, sensory motor func-
tion [22], cognitive function [23], and memory [22, 24].
Patients with higher negative scores of PANSS had more
perseverative errors (PE) and fewer completed categories
(CC) in the Wisconsin card sorting test (WCST) (standing
for executive function) [25], and poorer performance in
University of Pennsylvania Smell Identification Test (stand-
ing for function of an individual’s olfactory system) [26].
They also experienced more difficulties in the trail making
test (TMT) (standing for visual attention and executive
function), verbal fluency test (standing for semantic mem-
ory) [25], and faux pas test (standing for sociability) [27].
As mentioned, correlations exist between negative symp-
toms in patients with schizophrenia and neurocognitive
deficits. To get rid of clinical interference, we aimed to
patients with first-episode schizophrenia who were drug
naive. Thomas R. Insel pointed out that schizophrenia
should be regarded a collection of neurodevelopmental
disorders [2]. Since both symptoms and neurocognitive
deficits may be caused by neurodevelopmental problems in
adolescent patients with first-episode schizophrenia whose
prefrontal cortices are under development [28–30], it is
assumed that their negative symptoms are more closely
related to neurocognitive deficits than those of adult
patients with first-episode schizophrenia having developed
prefrontal cortices. If the aforementioned hypothesis is cor-
rect, the negative symptom scores of adolescent patients
with schizophrenia become more important in evaluating
neurocognitive deficits, compared with adult patients with
first-episode schizophrenia. It is easy for psychiatrists to
obtain patients’ PANSS scores, while evaluation of neuro-
cognitive functions is complicated and time-consuming.
That is to say, lower negative symptom scores indicate
stronger neurocognitive deficits in adolescent patients with
schizophrenia. In addition, improvement of patients’
negative symptoms can be used in evaluating the thera-
peutic effect.
The present study had two objectives (the first objective
was replication of the objective of previous studies to
some degree, while the second objective was novel):
1. To evaluate neurocognitive deficits and clinical
symptoms of patients with first-episode schizophrenia.
2. To study the relationship between negative
symptoms and neurocognitive functions in




This study included 92 patients with first-episode schizo-
phrenia and 57 healthy volunteers. All the patients were
divided into two groups—33 adolescent patients with
first-episode schizophrenia (whose age and age of onset
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were less than 18 years) and 59 adult patients with first-
episode schizophrenia (whose age and age of onset were
equal to or more than 18 years).
Patients were recruited from the First Affiliated Hospital
of Medicine School of Zhejiang University, who fulfilled
diagnostic criteria for schizophrenia in the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV). The Structured Clinical Interview for DSM-IV-
TR, routine laboratory tests, and physical and neurological
examinations were all administered to each participant.
Inclusion criteria for patient selection were as follows:
(1) age between 13 and 45 years; (2) having a DSM-IV
diagnosis of schizophrenia; (3) experiencing their first epi-
sode; (4) being drug naive; (5) both males and females;
and (6) ethnicity of Han origin. (Since the establishment
of People’s Republic of China, the national government
officially identifies 56 distinct ethnic groups according to
different dresses, music types, and languages, the largest
of which is the Han Chinese. Everybody in China belongs
to only one ethnic group that is marked on his/her iden-
tity card. Different ethnic groups mean different cultures
and cognitive abilities. The patients in the present study
all belonged to Han Chinese within three generations. In
this way, the interference of ethnic groups could be re-
duced.) Patients were excluded if they fell into any of the
following categories: (1) having a history or presence of
any severe unstable systemic disease; (2) having a history
of organic brain disease, cerebral trauma, seizure disorder,
mental retardation, or MRI evidence of structural brain
abnormalities; and (3) being pregnant, lactating, or plan-
ning to be pregnant within 6 months.
Volunteers through advertising served as normal con-
trols. None of the controls had a family history of men-
tal disorder or a medical history of somatic or organic
brain disease, cerebral trauma, severe mental retardation,
or MRI evidence of structural brain abnormalities. All
volunteers accepted MRI performed by experienced pro-
fessional staff in the First Affiliated Hospital of Medical
School of Zhejiang University using the Philips Magnetic
Resonance Imaging Systems Achieva 3.0T TX (Philips
Healthcare, Netherlands). The system was tested for data
stability before use. MRI was completed within 1 week
after neuropsychological tests. The age and education
level of the controls were matched to those of the patients.
The controls were of the same ethnic Han origin.
The study was approved by the ethics committee of the
First Affiliated Hospital of Medical School of Zhejiang
University, and conducted in accordance with the Code of
Ethics of the World Medical Association (Declaration of
Helsinki). All subjects and their legal guardians (applicable
if participants were less than 16 years old) provided writ-
ten informed consent before participating in the study.
The tests were completed for all subjects by fully trained
psychiatrists with consistent training courses in the First
Affiliated Hospital of Medical School of Zhejiang Univer-
sity. The inter-rater agreement of PANSS, WCST, continu-
ous performance test (CPT), TMT and Stroop color-word
test (SCWT) was measured, and the kappa coefficient was
0.80, 0.82, 0.78, 0.83, and 0.84, respectively. To reduce
errors, all items were assessed in the morning and neuro-
psychological tests were administered first. To minimize
the potential of order effects, the sequence of the neuro-
psychological tests was randomized. The tests usually lasted
1–2 h and were completed within 1 day for healthy people
and two consecutive days for patients. Clinical assessments
were rated on the same days as the aforementioned neuro-
psychological tests.
Neuropsychological assessments
Four neuropsychological assessments including WCST,
CPT, TMT, and SCWT were used in all 149 subjects (92
patients with first-episode schizophrenia and 57 healthy
controls). All of them were typical tests for patients with
schizophrenia in evaluating neurocognitive deficits stand-
ing for executive function; sustained, visual, and selective
attention; and so forth. In this study, standard Chinese
versions of neuropsychological assessments were used,
and the rater was blinded to grouping.
Wisconsin card sorting test (modified version)
The WCST was a cognitive task that predominantly
assessed executive function because of its reported sen-
sitivity to frontal lobe dysfunction [31]. Subjects were
asked to sort 48 cards on the basis of three possible cat-
egories (color, number, and shape). After six consecutive
correct responses, the subjects were asked to change the
sorting principle to another category. The test ended when
the subjects completed all six categories correctly or used
48 cards. The total trials (TT), correct trials (CT), total
number of errors (TE), PE, random errors (RE), and num-
ber of CC were recorded [32].
Continuous performance test
The CPT measured the subjects’ sustained and selective
attention. It was divided into three parts: (1) different
numbers appeared on the screen one by one, and the
mouse was clicked when “4” appeared; (2) eight numbers
appeared on the screen at the same time, and the mouse
was clicked when “4” appeared; and (3) eight numbers
appeared on the screen at the same time, and the mouse
was clicked when “7” appeared. Each number remained
on the screen for 150 ms, and the interval time was
550 ms. The subjects were asked to finish all the three
parts. The correct trials of three parts (CPT 1, CPT 2,
and CPT 3) and the perseverative errors in part 3 (PE
of CPT 3) were recorded [33].
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Trail making test
The TMT was a neuropsychological test of visual attention
and task switching, which provided information about vis-
ual search speed, processing speed, mental flexibility, and
executive functioning. It consisted of two parts in which
the subjects were instructed to connect a set of 25 dots as
fast and accurately as possible. In part 1 of TMT, the
subjects were required to quickly draw lines to connect
consecutively numbered circles. In part 2, the subjects
were asked to alternately combine numbers with differ-
ent colors in ascending order [34]. The task completion
was measured in seconds and recorded as TMT 1 and
TMT 2, respectively, for parts 1 and 2. TMT 1 was used
to examine cognitive processing speed, while TMT 2
referred to executive functioning [35].
Stroop color-word test
The SCWT, also called Stroop test, measured selective
attention, cognitive flexibility, and processing speed. It
was used as a tool in evaluating executive functions. In
step 1 of SCWT (SCWT 1), the subjects were asked to
read out three black words as fast as possible, which
stood for a certain color. Then, in step 2 (SCWT 2), they
were instructed to tell the color of three color parcels
as fast as possible. Finally, in step 3 (SCWT 3), they
were required to tell the color of three color words as
fast as possible, while each color was different from
the word’s meaning. The performance for each condi-
tion was calculated from the processing time per item
in seconds. The reaction time (RT of SCWT) differ-
ence in part 3 relative to part 2 was called the “inter-
ference” effect [36].
Clinical assessments
The PANSS [37] was used to assess the clinical symptom
severity in 92 patients with first-episode schizophrenia
in the time of the neuropsychological tests. The PANSS
was a 30-item medical scale, originally grouped into 3
parts, including 7 positive symptoms (i.e., delusions,
conceptual disorganization, hallucinations, hyperactivity,
grandiosity, suspiciousness/persecution, and hostility), 7
negative symptoms (i.e., blunted affect, emotional with-
drawal, poor rapport, passive/apathetic social withdrawal,
difficulty in abstract thinking, lack of spontaneity and flow
of conversation, and stereotyped thinking) and 16 general
psychopathology items (i.e., somatic concern, anxiety, guilt
feelings, tension, mannerisms and posturing, depression,
motor retardation, uncooperativeness, unusual thought
content, disorientation, poor attention, lack of judgment
and insight, disturbance of volition, poor impulse control,
preoccupation, and active social avoidance) that assessed
the degree of psychopathology on a number of symptom-
atic domains. Each item was rated from 1 (no evidence)
to 7 (extreme) based on objective criteria [37]. In this
study, standard Chinese versions of PANSS were used
to evaluate symptoms of 92 patients with first-episode
schizophrenia.
In recent years, the five-factor model has been widely
used in different schizophrenia research areas, including
cognitive function [14] and insight [38]. With the outcome
of principal component analysis and reliability analysis,
SI Tianmei suggested that the structure, validity, and
reliability of PANSS (Chinese version) were acceptable,
and put forward a five-factor model of Chinese-version
PANSS, including negative, positive, excitement–hostility,
anxiety depression, and cognitive defect factors [39].
In the study, the aforementioned five-factor model was
used.
Statistical analyses
All data were expressed as means ± standard deviation.
An unpaired t test and a chi-square test were used to
compare the general conditions and neuropsychological
assessment outcomes between patients and healthy people.
The relationship between general conditions and neuro-
psychological assessments of patients was computed using
a correlational analysis. A partial correlation was deter-
mined to control the potential influence of education level
on the relationship between the negative factor scores and
neuropsychological assessments. The difference in correl-
ation coefficients between adolescent and adult patients
with first-episode schizophrenia was computed by a Fisher’s
Z test. The false discovery rate was used to control the
inflated Type I error rate. To get convincing results, all
statistical tests were two-tailed and a p-value < .05 was
considered to be significant.
All analyses were carried out using the Statistical Package
for the Social Sciences (SPSS) version 18.0 for Windows
(IBM, IL, USA).
Results
Demographics, neuropsychological assessments, and
clinical assessments
No significant difference was found in age (t = −.697,
p = .487), education level (t = −1.832, p = .070), or gender
(χ2 = .129, p = .625) between patients with first-episode
schizophrenia and healthy people.
In the WCST, the mean scores of CTand CC for patients
with schizophrenia were lower than those of controls,
while the mean scores of TE, PE, and RE for patients with
schizophrenia were higher than those of controls (all
p-values < .01). However, no significant difference was
observed in TT (t = .763, p = .447).
The results of TMT and SCWT were similar to those
of WCST. Compared with the controls, patients with
schizophrenia spent more time in TMT 1 (t = 2.460,
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p = .015), TMT 2 (t = 2.777, p = .006), SCWT 2 (t = 6.574,
p < .001), SCWT 3 (t = 7.867, p < .001) and RT of SCWT
(t = 5.000, p < .001). In the CPT, patients with first-episode
schizophrenia got a higher mean score of PE of CPT 3
compared with healthy people (t = 2.022, p = .045). The
details are displayed in Table 1.
The mean score of CPT 2 for adolescent patients with
first-episode schizophrenia was lower than that of adults
(t = −2.064, p = .043). However, no other significant differ-
ence was noted in clinical or neuropsychological assess-
ments between adolescent and adult patients with first-
episode schizophrenia. The details are displayed in Table 2.
Correlational analysis between clinical assessments
and neuropsychological assessments in patients with
first-episode schizophrenia
Using the five-factor model of PANSS, the negative factor
scores were computed using an average of nine items (i.e.,
Blunted Affect, Emotional Withdrawal, Poor Rapport,
Passive/Apathetic Social Withdrawal, Lack of Spontaneity
and Flow of Conversation, Motor Retardation, Disturbance
of Volition, Preoccupation, and Active Social Avoidance).
Pearson correlational analysis was performed to assess the
relationship between general conditions, negative symp-
toms, and neuropsychological assessments outcomes.
Considering the general conditions, significant corre-
lations were found between the educational level and
neuropsychological assessments on nine items, especially
on TMT 1 (r = −.462, p < .001), TMT 2 (r = −.473, p < .001),
SCWT 1 (r = −.406, p < .001), and SCWT 2 (r = −.432,
p < .001). In addition, it has been reported in a previous
study that sustained attention, ideation fluency, cogni-
tive flexibility, and visuospatial memory had a positive
correlation with education in deficit schizophrenia [40].
Partial correlation analysis was used to get rid of the
interference. With the variable of education level con-
trolled, persuasive results were obtained. In total, signifi-
cant correlations were observed between the negative
Table 1 Demographic, neuropsychological assessments and clinical assessments outcomes of first-episode schizophrenics and
healthy people
First-episode schizophrenics (N = 92) Healthy people (N = 57) t/χ2 P-value
Age (years) 22.86 ± 7.82 23.84 ± 8.69 -.697 .487
Education level (years) 10.77 ± 3.01 11.77 ± 3.38 -1.832 .070
Duration of illness (months) 12.26 ± 18.37 None None None
Gender (male/total) 36/92 24/57 .129 .625
PANSS T 84.18 ± 16.71 None None None
P 23.88 ± 7.37 None None None
N 19.30 ± 8.12 None None None
G 41.00 ± 8.32 None None None
WCST TT 47.34 ± 2.73 47.04 ± 2.08 .763 .447
CT 25.42 ± 10.47 33.91 ± 7.30 -5.821 < .001
TE 21.80 ± 10.56 12.77 ± 8.18 5.846 < .001
PE 13.82 ± 7.54 7.56 ± 4.99 6.089 < .001
RE 7.96 ± 5.00 5.49 ± 3.94 3.342 .001
CC 2.87 ± 2.06 4.68 ± 1.68 -5.872 < .001
CPT CPT 1 11.01 ± 2.27 11.18 ± .80 -.635 .527
CPT 2 11.63 ± 3.33 12.12 ± 1.65 -1.201 .232
CPT 3 11.95 ± 2.99 12.23 ± 1.28 -.795 .428
PE of CPT 3 .84 ± 1.75 .37 ± 1.08 2.022 .045
TMT TMT 1 58.13 ± 34.06 43.56 ± 35.77 2.460 .015
TMT 2 114.31 ± 62.47 84.51 ± 64.39 2.777 .006
SCWT SCWT 1 50.82 ± 15.19 44.96 ± 21.87 1.772 .080
SCWT 2 90.16 ± 33.32 62.51 ± 17.90 6.574 < .001
SCWT 3 143.27 ± 49.19 97.51 ± 22.82 7.687 < .001
RT of SCWT 53.10 ± 29.27 35.00 ± 14.72 5.000 < .001
Values are the means ± SD. All P-values were compared with Healthy people analyzed by an unpaired t-test
T PANSS total scores, P positive syndrome scale scores, N negative syndrome scale scores, G general psychopathology syndrome scale scores, TT total trials,
CT correct trials, TE total number of errors, PE perseverative errors, RE random errors, CC the number of completed categories, PE of CPT 3 perseverative errors of
CPT 3, RT of SCWT reaction time of SCWT;
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factor scores and neuropsychological assessments on 12
items (i.e., CT, TE, PE, RE and CC of WCST; CPT 1;
TMT 1 and TMT 2; SCWT 1, SCWT 2, SCWT 3, and
RT of SCWT). Moreover, the negative factor score was
moderately correlated to SCWT 1 (r = .410, p < .001)
and SCWT 3 (r = .409, p < .001). The details are displayed
in Table 3.
Comparison of adolescent and adult patients with
first-episode schizophrenia
In both adolescent and adult patients with schizophrenia,
the negative factor score was correlated with more time
spent in part 1 (r = .527, p = .002; r = .342, p = .009), part 2
(r = .400, p = .023; r = .365, p = .005), and part 3 (r = .552,
p = .001; r = .452, p < .001) of SCWT, a lower mean score
of CT (r = −.486, p = .005; r = −.313, p = .017), higher mean
scores of TE (r = .489, p = .005; r = .297, p = .024), and RE
of WCST (r = .488, p = .005; r = .310, p = .018). No signifi-
cant difference was found in the aforementioned items of
correlation coefficients (all p-values > .05) between the
two groups. The details are displayed in Table 4.
In adolescent patients with schizophrenia, the negative
factor score was strongly correlated with more time
spent in TMT 1 (r = .646, p < .001) and TMT 2 (r = .663,
p < .001), and moderately or weakly correlated with a
higher mean score of PE (r = .425, p = .015) of WCST and
lower mean scores of CPT 2 (r = −.425, p = .015). How-
ever, no correlation between the aforementioned items
could be found in adult patients.
The negative factor score was weakly correlated with a
lower mean score of CPT 3 (r = −.385, p = .030) in ado-
lescent patients with schizophrenia, while it was weakly
correlated with a higher mean score of CPT 3 (r = .303,
p = .021) in adults. The details are displayed in Table 5.
Discussion
The most important finding in the present study was sig-
nificant correlations between the negative factor scores
and most neuropsychological assessments in patients with
Table 2 Demographic, neuropsychological assessments and clinical assessments outcomes of adolescent and adult first-episode
schizophrenics
Adolescent first-episode schizophrenics (N = 33) Adult first-episode schizophrenics (N = 59) t P-value
Age (years) 15.48 25.02 −10.107 < .001
Education level (years) 9.61 11.42 −3.518 .001
Duration of illness (months) 9.67 ± 1.50 11.42 ± 3.43 −1.182 .240
PANSS T 85.30 ± 18.04 83.56 ± 16.04 .462 .645
P 23.33 ± 7.21 24.19 ± 7.50 -.537 .593
N 20.45 ± 10.26 18.66 ± 6.65 .904 .371
G 41.52 ± 8.70 40.71 ± 8.16 .434 .666
WCST TT 47.64 ± 1.11 47.17 ± 3.30 .990 .325
CT 24.06 ± 9.62 26.19 ± 10.92 -.968 .336
TE 23.27 ± 10.15 20.98 ± 10.78 1.015 .314
PE 14.64 ± 6.28 13.36 ± 8.18 .840 .403
RE 8.55 ± 5.10 7.63 ± 4.95 .837 .406
CC 2.64 ± 2.07 3.00 ± 2.05 -.810 .421
CPT CPT 1 10.79 ± 2.30 11.14 ± 2.25 -.700 .486
CPT 2 10.67 ± 3.45 12.17 ± 3.16 −2.064 .043
CPT 3 11.61 ± 3.65 12.14 ± 2.57 -.738 .464
PE of CPT 3 .61 ± 1.48 .97 ± 1.88 −1.013 .314
TMT TMT 1 57.85 ± 30.69 58.28 ± 36.06 -.061 .951
TMT 2 104.68 ± 48.052 119.69 ± 69.05 −1.223 .225
SCWT SCWT 1 50.50 ± 16.44 50.99 ± 14.59 -.145 .885
SCWT 2 88.25 ± 30.03 91.23 ± 35.23 -.430 .669
SCWT 3 134.98 ± 33.04 147.90 ± 55.98 −1.391 .168
RT of SCWT 46.74 ± 19.66 56.66 ± 33.09 −1.804 .075
Values are the means ± SD. All P-values were compared with Healthy people analyzed by an unpaired t-test
T PANSS total scores, P positive syndrome scale scores, N negative syndrome scale scores, G general psychopathology syndrome scale scores, TT total trials,
CT correct trials, TE total number of errors, PE perseverative errors, RE random errors, CC the number of completed categories, PE of CPT 3 perseverative errors
of CPT 3, RT of SCWT reaction time of SCWT;
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first-episode schizophrenia, with stronger correlations in
adolescent patients. Most previous findings [22, 23] indi-
cated that more attention should be paid to patients with
first-episode schizophrenia who are drug naïve, to reduce
the interference of drugs with symptoms and neurocogni-
tive functions, and also to the differences between adoles-
cence and adults.
On one hand, patients diagnosed with schizophrenia
showed neurocognitive deficits in most assessments com-
pared with healthy people, including executive function;
visual search and processing speed; sustained, selective,
and visual attention; and mental and cognitive flexibility.
The present results were similar to many previous re-
ports in the literature, which suggested that patients
with schizophrenia showed deficits in executive func-
tion [31], visual attention, visual search speed, processing
speed, mental flexibility [35] and selective attention [36].
That is to say, schizophrenia is a mental disorder that
affects one’s neurocognitive function [2]. Some brain
imaging examinations such as magnetic resonance tom-
ography and positron emission tomography–computed
tomography supported that abnormal functional areas
in the brain of patients with schizophrenia may usually
appear in the frontal lobes and temporal lobes [4]. The
frontal lobe plays an important role in executive func-
tion, including the ability to forecast future outcomes
resulting from present decisions, to determine better or
worse choices, to deal with social emergencies, and to
distinguish similarities and differences. The functions
of temporal lobes cover reserving visual memories, pro-
cessing sensory input, understanding language, keeping
new memories and emotions, and extending in meaning.
Some correlations may exist between abnormal activity of
massive brain regions and neurocognitive function deficits
in patients with schizophrenia [2]. Thus far, imaging ex-
aminations have been completed in some of these 149
subjects, and the details will be discussed in future studies.
On the other hand, No significant difference was observed
Table 3 The correlation and partial correlation (negative factor) matrix of general conditions, negative symptoms and neuropsychological
assessments outcomes on first-episode schizophrenics
Age Age of onset Education level Duration of illness Negative factor
WCST TT -.032 -.030 .004 -.011 -.010
CT .044 -.028 .276** -.075 -.381**
TE -.045 .028 -.271** .078 .381**
PE -.034 .043 -.257* .086 .272**
RE -.033 -.001 -.159 .002 .397**
CC -.028 -.084 .283** -.044 -.290**
CPT CPT 1 .242* .179 .141 .251* -.230*
CPT 2 .187 .192 -.044 .148 -.178
CPT 3 .040 .002 .056 -.090 -.080
PE of CPT 3 .051 .099 -.007 .024 -.045
TMT TMT 1 -.009 .175 -.462** .016 .306**
TMT 2 .043 .222* -.473** .014 .293**
SCWT SCWT 1 .087 .156 -.406** .055 .410**
SCWT 2 -.067 .087 -.432** .072 .331**
SCWT 3 -.063 -.013 -.206* -.104 .409**
RT of SCWT -.029 -.120 .145 -.256* .335**
False Discovery Rate: p (CT) < p (TE) < p (RE) < p (SCWT 1) < p (SCWT 3) < p (SCWT 2) < p (RT of SCWT) < p (TMT 1) < p (CC) < p (TMT 2) < p (PE) < p (CPT 1) < .05 <
p (CPT 2) < p (CPT 3) < p (PE of CPT 3) < p (TT), while p (CPT 1) = .028 < .05*12/16 = .0375
|r|∈[.8,1] means highly strong correlation, |r|∈[.6,.8) means strong correlation, |r|∈[.4,.6) means moderate correlation, |r|∈[.2,.4) means weak correlation, |r|∈[0,.2)
means very weak correlation or no correlation
TT total trials, CT correct trials, TE total number of errors, PE perseverative errors, RE random errors, CC the number of completed categories; PE of CPT 3
perseverative errors of CPT 3, RT of SCWT reaction time of SCWT
*P < .05, **P < .01, the significance of the correlation coefficient
Table 4 The comparison of correlation coefficients between
adolescent and adult first-episode schizophrenics
Adolescent (N = 33) Adult (N = 59) u-value P-value
r z r z
WCST CT -.486** -.531 -.313* -.324 -.915 .358
TE .489** .535 .297* .306 1.010 .312
RE .488** .533 .310* .321 .941 .347
SCWT SCWT 1 .527** .586 .342** .356 1.015 .308
SCWT 2 .400* .424 .365** .383 .181 .857
SCWT 3 .552** .621 .452** .487 .592 .555
CT correct trials, TE total number of errors, RE random errors
*P < .05, **P < .01, the significance of the correlation coefficient
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in clinical or neuropsychological assessments between
adolescent and adult patients with first-episode schizo-
phrenia, but some previous studies showed that adoles-
cent patients with schizophrenia performed worse than
adult patients in tasks of working memory, language, and
motor function [21].
Significant correlations were obtained between nega-
tive symptoms and most neuropsychological assessments
(CT, TE, PE, RE, and CC of WCST; CPT 1; TMT 1 and
TMT 2; SCWT 1, SCWT 2, SCWT 3, and RT of SCWT)
in patients with first-episode schizophrenia. It meant that
the severity of negative symptoms was correlated with the
deficits of executive function, sustained, selective, and visual
attention, visual search and processing speed, and mental
and cognitive flexibility in patients with schizophrenia [32,
33, 35, 36]. A previous similar study showed that negative
symptoms were associated with neurocognitive function
deficits involving executive function, sustained attention
function [22], and cognitive function [23].
Most importantly, the present findings suggested closer
correlations between the negative factor scores and some
neuropsychological assessments outcomes in adolescent
patients with first-episode schizophrenia, including more
time spent in TMT 1 and TMT 2, fewer times of CPT 2,
and a higher mean score of PE of WCST, compared with
adult patients. Therefore, the severity of negative symp-
toms in adolescent patients with schizophrenia was more
related to their neurocognitive deficits of visual, selective,
and sustained attention; visual search and processing speed;
mental flexibility; and executive function [36–38]. Some of
the latest studies regarded schizophrenia as a collection
of “neurodevelopmental disorders,” because it nearly
emerged in late adolescence or early adulthood when the
prefrontal cortex was still developing [2, 28–30]. The
present results partly support the conclusion. Since
adolescence is a key period of neurological and psycho-
logical development, earlier schizophrenia symptoms and
neurocognitive deficits may both originate from earlier
neurodevelopmental problems in adolescent patients with
first-episode schizophrenia.
Hence, the negative symptoms of adolescent patients
with schizophrenia are more closely related to their neu-
rocognitive deficits, compared with adult patients with
first-episode schizophrenia. For physicians, the negative
symptom scores of PANSS become more important in
evaluating neurocognitive deficits of adolescent patients
with first-episode schizophrenia. Because it is easy for
psychiatrists to obtain symptom characteristics from psy-
chiatric examinations, PANSS scores, and description of
patients or their family members, the physicians can
view the severity of negative symptoms as a factor that
infers neurocognitive deficits in patients with first-episode
schizophrenia, especially adolescents. The evaluation of
neurocognitive functions is complicated and time-
consuming. First-visit adolescent outpatients with obvious
negative symptoms may suggest serious neurocognitive def-
icits. Furthermore, the severity of negative symptoms can
be widely used in evaluating the therapeutic effect.
The present study had several limitations. (1) The sam-
ple size was small. (2) The ratio of male and female partic-
ipants was different between groups. (3) The study did not
contain any follow-up data. (4) The study lacked neuroim-
aging examinations. (5) The cutoff age remained unclear.
In this study, a total of 92 patients with schizophrenia
were divided into two groups—33 adolescent patients with
first-episode schizophrenia (whose age and age of onset
were less than 18 years) and 59 adult patients with first-
episode schizophrenia (whose age and age of onset were
equal to or more than 18 years), which meant the cutoff
age was 18 years. However, recent research has regarded
schizophrenia to comprise four stages (i.e., stage 1:
Table 5 The correlation matrix of negative factor scores and




WCST TT -.010 .050 -.059
CT -.381** -.486** -.313*
TE .381** .489** .297*
PE .272** .425* .199
RE .397** .488** .310*
CC -.290** -.352 -.214
CPT CPT 1 -.230* -.368 -.094
CPT 2 -.178 -.425* .081
CPT 3 -.080 -.385* .303*
PE of CPT 3 -.045 .221 -.150
TMT TMT 1 .306** .646** .101
TMT 2 .293** .663** .173
SCWT SCWT 1 .410** .527** .342**
SCWT 2 .331** .400* .365**
SCWT 3 .409** .552** .452**
RT of SCWT .335** .318 .412**
Adolescent False Discovery Rate: p (TMT 1) < p (TMT 2) < p (SCWT 3) < p (SCWT 1)
< p (CT) < p (TE) < p (RE) < p (PE) < p (CPT 2) < p (SCWT 2) < p (CPT 3) < p (CPT 1) <
p (CC) < .05 < p (RT of SCWT) < p (PE of CPT 3) < p (TT), while p (CPT 3) = .03
< .05*11/16 = .034 and p (CPT 1) = .038 > .05*12/16 = .0375. So CC and CPT 1 are
not significant
Adult False Discovery Rate: p (SCWT 3) < p (RT of SCWT) < p (SCWT 2) < p (SCWT 1)
< p (CT) < p (RE) < p (CPT 3) < p (TE) < .05 < p (CC) < p (PE) < p (TMT 2) < p (PE of
CPT 3) < p (TMT 1) < p (CPT 1) < p (CPT 2) < p (TT), while
p (TE) = .024 < .05*8/16 = .025
|r|∈[.8,1] means highly strong correlation, |r|∈[.6,.8) means strong correlation,
|r|∈[.4,.6) means moderate correlation, |r|∈[.2,.4) means weak correlation,
|r|∈[0,.2) means very weak correlation or no correlation
TT total trials, CT correct trials, TE total number of errors, PE perseverative
errors, RE random errors, CC the number of completed categories, PE of CPT 3
perseverative errors of CPT 3, RT of SCWT reaction time of SCWT
*P < .05, **P < .01, the significance of the correlation coefficient
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<12 years, risk stage; stage 2: 12–18 years, prodromal
stage; stage 3: 18–24 years, psychosis stage; stage 4:
>24 years, chronic disabled stage) [2]. Thus, it would
be better that more cutoff points are set in future studies.
In summary, clinical negative symptoms are good in-
dexes for evaluating neurocognitive deficits in patients
with schizophrenia. In adolescent patients, doctors should
pay more attention to negative symptom results of PANSS.
Also, more brain imaging data should be collected to
support the conclusions. Moreover, longer-term studies
with a larger sample size are needed to draw more
definite conclusions.
Conclusions
1. Patients with first-episode schizophrenia show
neurocognitive deficits in most neuropsychological
assessments compared with healthy people.
2. The severity of negative symptoms in patients with
first-episode schizophrenia is related to some of their
neurocognitive deficits.
3. Most importantly, this relationship is even closer for
adolescent patients with first-episode schizophrenia.
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